Linda M Niccolai1, Niti R Mehta, James L Hadler. 1. Yale School of Public Health Division of Epidemiology of Microbial Diseases, Yale University, New Haven, Connecticut 06520, USA. linda.niccolai@yale.edu
Abstract
BACKGROUND: Two vaccines against human papillomavirus (HPV), a necessary cause of cervical cancer, are currently licensed and recommended for routine administration in the U.S. to girls in a three-dose series. PURPOSE: This study examined effects of race/ethnicity, poverty, and year on completion of the three-dose HPV vaccine series among those who initiated vaccination. METHODS: Data from the 2008-2009 National Immunization Survey-Teen for girls aged 13-17 years who received at least one dose of HPV vaccine (n=7606) were analyzed in 2010-2011 using logistic regression to adjust for covariates including measures of access to care. RESULTS: During this 2-year period, 55% of adolescent girls who initiated vaccination completed the three-dose series. Completion was significantly higher in 2009 (60%) compared to 2008 (48%; p<0.001). After controlling for covariates, adolescents who were black (AOR=0.48, 95% CI=0.40, 0.57) or Hispanic (AOR=0.75, 95% CI=0.64, 0.88) were significantly less likely to complete vaccination than whites. Adolescents living below the federal poverty level were significantly less likely to complete vaccination than adolescents with household incomes >$75,000 (AOR=0.76, 95% CI=0.63, 0.92). There was no significant interaction between race/ethnicity and year (p=0.92). Although poverty was associated with lower completion rates in 2008, this association was not observed in 2009 (p<0.05 for poverty-year interaction). CONCLUSIONS: HPV vaccination completion rates increased between 2008 and 2009. However, significant differences by race/ethnicity and poverty were observed, and the racial/ethnic differences persisted.
BACKGROUND: Two vaccines against human papillomavirus (HPV), a necessary cause of cervical cancer, are currently licensed and recommended for routine administration in the U.S. to girls in a three-dose series. PURPOSE: This study examined effects of race/ethnicity, poverty, and year on completion of the three-dose HPV vaccine series among those who initiated vaccination. METHODS: Data from the 2008-2009 National Immunization Survey-Teen for girls aged 13-17 years who received at least one dose of HPV vaccine (n=7606) were analyzed in 2010-2011 using logistic regression to adjust for covariates including measures of access to care. RESULTS: During this 2-year period, 55% of adolescent girls who initiated vaccination completed the three-dose series. Completion was significantly higher in 2009 (60%) compared to 2008 (48%; p<0.001). After controlling for covariates, adolescents who were black (AOR=0.48, 95% CI=0.40, 0.57) or Hispanic (AOR=0.75, 95% CI=0.64, 0.88) were significantly less likely to complete vaccination than whites. Adolescents living below the federal poverty level were significantly less likely to complete vaccination than adolescents with household incomes >$75,000 (AOR=0.76, 95% CI=0.63, 0.92). There was no significant interaction between race/ethnicity and year (p=0.92). Although poverty was associated with lower completion rates in 2008, this association was not observed in 2009 (p<0.05 for poverty-year interaction). CONCLUSIONS:HPV vaccination completion rates increased between 2008 and 2009. However, significant differences by race/ethnicity and poverty were observed, and the racial/ethnic differences persisted.
Authors: Kathy L MacLaughlin; Robert M Jacobson; Jennifer L St Sauver; Debra J Jacobson; Chun Fan; Chung-Il Wi; Lila J Finney Rutten Journal: Vaccine Date: 2020-07-24 Impact factor: 3.641
Authors: Madina Agénor; Ashley E Pérez; Sarah M Peitzmeier; Jennifer Potter; Sonya Borrero Journal: J Womens Health (Larchmt) Date: 2018-06-29 Impact factor: 2.681
Authors: James L Klosky; Kathryn M Russell; Jessica L Simmons; Rebecca H Foster; Kelly Peck; Daniel M Green; Melissa M Hudson Journal: Pediatr Blood Cancer Date: 2015-04-20 Impact factor: 3.167
Authors: Natasha L Underwood; Paul Weiss; Lisa M Gargano; Katherine Seib; Kimberly J Rask; Christopher Morfaw; Dennis Murray; Ralph J DiClemente; James M Hughes; Jessica M Sales Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Peng-Jun Lu; Walter W Williams; Jun Li; Christina Dorell; David Yankey; Deanna Kepka; Eileen F Dunne Journal: Am J Prev Med Date: 2013-04 Impact factor: 5.043